Intervention Review

You have free access to this content

HMG CoA reductase inhibitors (statins) for dialysis patients

  1. Suetonia C Palmer1,
  2. Sankar D Navaneethan2,
  3. Jonathan C Craig3,4,
  4. David W Johnson5,
  5. Vlado Perkovic6,
  6. Sagar U Nigwekar7,
  7. Jorgen Hegbrant8,
  8. Giovanni FM Strippoli3,4,9,10,11,*

Editorial Group: Cochrane Kidney and Transplant Group

Published Online: 11 SEP 2013

DOI: 10.1002/14651858.CD004289.pub5


How to Cite

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Nigwekar SU, Hegbrant J, Strippoli GFM. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database of Systematic Reviews 2013, Issue 9. Art. No.: CD004289. DOI: 10.1002/14651858.CD004289.pub5.

Author Information

  1. 1

    University of Otago Christchurch, Department of Medicine, Christchurch, New Zealand

  2. 2

    Glickman Urological and Kidney Institute, Cleveland Clinic, Department of Nephrology and Hypertension, Cleveland, OH, USA

  3. 3

    The University of Sydney, Sydney School of Public Health, Sydney, NSW, Australia

  4. 4

    The Children's Hospital at Westmead, Cochrane Renal Group, Centre for Kidney Research, Westmead, NSW, Australia

  5. 5

    Princess Alexandra Hospital, Department of Nephrology, Woolloongabba, Queensland, Australia

  6. 6

    The George Institute for Global Health, Renal and Metabolic Division, Camperdown, NSW, Australia

  7. 7

    Harvard Medical School, Brigham and Women's Hospital, Massachusetts General Hospital, Scholars in Clinical Sciences Program, Boston, MA, USA

  8. 8

    Diaverum Renal Services Group, Medical Office, Lund, Sweden

  9. 9

    University of Bari, Department of Emergency and Organ Transplantation, Bari, Italy

  10. 10

    Mario Negri Sud Consortium, Department of Clinical Pharmacology and Epidemiology, Santa Maria Imbaro, Italy

  11. 11

    Diaverum, Medical-Scientific Office, Lund, Sweden

*Giovanni FM Strippoli, Cochrane Renal Group, Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, 2145, Australia. strippoli@negrisud.it. gfmstrippoli@gmail.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 11 SEP 2013

SEARCH

[Figure 1]
Figure 1. Study selection flow diagram
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies
[Figure 3]
Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study
[Analysis 1.1]
Analysis 1.1. Comparison 1 Statin versus placebo or no treatment, Outcome 1 Major cardiovascular events.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Statin versus placebo or no treatment, Outcome 2 All-cause mortality.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Statin versus placebo or no treatment, Outcome 3 Cardiovascular mortality.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Statin versus placebo or no treatment, Outcome 4 Fatal and non-fatal myocardial infarction.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Statin versus placebo or no treatment, Outcome 5 Fatal and non-fatal stroke.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Statin versus placebo or no treatment, Outcome 6 Elevated creatine kinase.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Statin versus placebo or no treatment, Outcome 7 Elevated liver function enzymes.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Statin versus placebo or no treatment, Outcome 8 Withdrawal due to adverse events.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Statin versus placebo or no treatment, Outcome 9 Cancer.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Statin versus placebo or no treatment, Outcome 10 Total cholesterol.
[Analysis 1.11]
Analysis 1.11. Comparison 1 Statin versus placebo or no treatment, Outcome 11 LDL cholesterol.
[Analysis 1.12]
Analysis 1.12. Comparison 1 Statin versus placebo or no treatment, Outcome 12 Triglycerides.
[Analysis 1.13]
Analysis 1.13. Comparison 1 Statin versus placebo or no treatment, Outcome 13 HDL cholesterol.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Statin versus another statin, Outcome 1 Elevated liver function enzymes.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Statin versus another statin, Outcome 2 Withdrawal due to adverse events.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Statin versus another statin, Outcome 3 Total cholesterol.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Statin versus another statin, Outcome 4 LDL cholesterol.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Statin versus another statin, Outcome 5 Triglycerides.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Statin versus another statin, Outcome 6 HDL cholesterol.